Review Article

Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation for Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials

Dan Wang,1 Hongshuo Shi,1 Zhenguo Yang,2 Wenbin Liu,2 Lu Qi,2 Chengda Dong,3 Guomin Si,4 and Qi Guo5

1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
2The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
3First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China
4Department of Traditional Chinese Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
5Department of Aviation Disease, The 960 Hospital of PLA, Jinan, China

Correspondence should be addressed to Qi Guo; nationalflag@qq.com

Received 2 January 2022; Accepted 29 March 2022; Published 14 April 2022

Academic Editor: Noureddin Nakhostin Ansari

Copyright © 2022 Dan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This meta-analysis aims to evaluate the effectiveness and safety of transcutaneous electrical acupoint stimulation (TEAS) in treating post-operative pain. Methods. This meta-analysis was registered in PROSPERO (CRD42021286753). We searched PubMed, Embase, and the Cochrane Library for relevant randomized controlled trials (RCTs) about TEAS in treating postoperative pain that were published before November 2021. The primary outcome was visual analogue scale (VAS) within 24 h after surgery. The secondary outcomes included postoperative opioid analgesic drug consumption and the occurrence of adverse reactions within the postoperative 24–72 h. Adverse reactions included dizziness, nausea, and vomiting. Continuous variables were analyzed using mean difference (MDs) or standardized mean difference (SMDs) and 95% CIs. Relative risk (RR) and 95% CI were used for dichotomous data. The data were pooled and analyzed by RevMan 5.4 and STATA15.0 software. Results. Seventeen trials with 1375 participants were included. The current results suggested that application of TEAS showed obvious superiority in reducing VAS scores (SMD = −1.51, 95% CI = −2.20∼−0.82, I2 = 96%). Subgroup analysis was performed according to open surgery and minimally invasive surgery. VAS scores were decreased after surgery at 24 h (SMD = −0.84, 95% CI = −1.07∼−0.6, I2 = 96%; SMD = −0.88, 95% CI = −1.02∼−0.75, I2 = 96%). The incidence of postoperative dizziness and nausea and vomiting was significantly lower in the TEAS group within postoperative 24–72 h (RR = 0.48, 95% CI = 0.34∼0.68, I2 = 0%; RR = 0.66, 95% CI = 0.44–1.01, I2 = 69%; and RR = 0.49, 95% CI = 0.24–1.00, I2 = 51%). Postoperative opioid analgesics were also reduced in the TEAS group within 72 h after surgery (SMD = −2.10, 95% CI = −3.37∼−0.82, I2 = 96%). Conclusions. TEAS can reduce postoperative pain as well as the incidence of dizziness, nausea, and vomiting and the number of analgesics used after surgery. TEAS is a reasonable modality to incorporate into a multimodal management approach for postoperative pain.

1. Introduction

Postoperative pain, including acute postoperative pain and persistent chronic postoperative pain, remains a main clinical problem [1]. In 2020, the current International Association for the Study of Pain (IASP) defined pain as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damages” [2]. A 2011 report from the US National Institutes of Health states that more than 80% of patients suffer postoperative pain, with fewer than 50% receiving adequate pain relief [3]. US surveys from 1993, 2003, and 2012 have shown that postoperative pain is common and remains undertreated, and that the distribution and quality of perceived pain have remained largely unchanged [3]. Evidence suggests that less than half of patients who undergo
surgery report adequate postoperative pain relief and about 10% of postoperative pain develops into chronic pain [4]. In addition to impairing the patient’s comfort, inadequately controlled pain negatively affects quality of life, function, and functional recovery, increases the risk of postsurgical complications. Postoperative pain not only reduces patients’ satisfaction about the healthcare system but also prolongs the length of hospital stay and healthcare costs. Postoperative pain management is still based on the use of traditional opioids such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and local anesthetics [5]. A recent retrospective review based on more than 300,000 patients across 380 US hospitals showed that about 95% of surgical patients were treated with opioids [3]. However, opioids have many side-effects that range from bothersome to life-threatening, including nausea, vomiting, constipation, oversedation, somnolence, and respiratory depression [6]. NSAIDs can be responsible for several well-known side effects, comprising upper gastrointestinal bleeding and cardiovascular disease [7]. Local anesthetics are widely used in various fields, but the long-term effects of local anesthetics can lead to adverse conditions, such as inhibition of central and respiratory circulation, and even death of patients [8]. Therefore, it is particularly urgent to find a more efficient way to manage postoperative pain.

Transcutaneous electrical acupoint stimulation (TEAS) is a noninvasive form of electrical acupoint stimulation. Instead of traditional acupuncture intervention, which involves inserting a needle into an acupoint and applying manual stimulation including acupuncture and electroacupuncture, the stimulation on the acupoint is delivered through electricity which is delivered through the surface electrodes [9]. Modern medical research has proved that acupuncture treatment can inhibit the body’s pain conduction [10], promote local blood circulation [11], improve the immunity of the patients [12], and enhance the body’s anti-inflammatory and metabolic ability [13]. All of these mechanisms can have a rapid analgesic effect. However, there is still a lack of strong clinical evidence to confirm its effectiveness and safety in treating patients with postoperative pain. Therefore, we performed this meta-analysis to assess the effectiveness and safety of TEAS in the treatment of postoperative pain. The primary outcome is the visual analogue scale (VAS) within 24 h after surgery. While the secondary outcomes include postoperative analgesic drug consumption and the occurrence of adverse reactions within postoperative 24–72 h. Adverse reactions included dizziness, nausea, and vomiting.

2. Materials and Methods

2.1. Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

2.2. Inclusion and Exclusion Criteria. Two authors independently identified the eligibilities of articles for in-depth examination by using the following inclusion: (1) The type of research should be a randomized controlled trial (RCT), and the language is limited to English. (2) Patients of any age and gender with postoperative pain, and if there are other causes of pain will be excluded. (3) The intervention in the experimental group was TEAS (patients in this group received electrical stimulation on the target acupoints. The stimulation was provided by an electrical stimulator through electrode tabs on the target acupoints. The electrical stimulator was set at certain modes, frequency, and intensity accordingly), and the control group was treated with sham-TEAS, blank control, or the same intervention as the treatment group other than TEAS will also be included. (4) Articles involved in evaluating the effectiveness of TEAS on postoperative pain. The exclusion criteria were as follows: (1) article types of comments, case reports, crossover studies, letters, editorials, review articles, meta-analysis, and retrospective studies; (2) studies of animal experiments; and (3) studies involving data that cannot be extracted or lacking adequate data. If discrepancies existed, final decisions were reached via consensus of all authors.

2.3. Search Strategy. The meta-analysis was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [14] and is reported in compliance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [15]. This meta-analysis was prospectively registered in PROSPERO (CRD42021286753). We searched PubMed, Embase, and the Cochrane Library from inception to November 2021, without any restrictions. The search terms included terms related to TEAS (e.g., “transcutaneous electrical acupoint stimulation” OR “TEAS” OR “transcutaneous acupoint electrical stimulation” OR “acupuncture”) and terms related to postoperative pain (e.g., “post-operative analgesia” OR “pain, post-operative” OR “pain management” OR “ache” OR “ache+”) (Table 1). There were no restrictions on dates, sex, or age, or type of surgery. We searched for these terms in the titles and abstracts of potentially relevant papers. The references of the retrieved papers were also reviewed for further relevant studies. The lists of references of retrieved articles will be searched for identifying potentially eligible trials.

| Number | Search terms |
|--------|--------------|
| 1      | "Postoperative pain"/exp |
| 2      | "Postoperative pain"/ab, ti |
| 3      | "Postoperative analgesi"/ab, ti |
| 4      | "Pain management"/ab, ti |
| 5      | ache"/ab, ti |
| 6      | "1 OR 2 OR 3 OR 4 OR 5 |
| 7      | "Transcutaneous electrical acupoint stimulation"/ab, ti |
| 8      | "Transcutaneous acupoint electrical stimulation"/ab, ti |
| 9      | electroacupuncture"/ab, ti |
| 10     | “Electro acupuncture”/ab, ti |
| 11     | teas: ab, ti |
| 12     | "7 OR 8 OR 9 OR 10 OR 11 |
| 13     | 6 AND 12 |
Figure 1: Flow diagram of study selection.

Table 2: Characteristic of the included studies.

| Trial                  | Year | Sample size | Interventions | Acupoint selections | Target outcomes | Type of surgery          |
|------------------------|------|-------------|---------------|---------------------|----------------|--------------------------|
|                        |      | (n)         | TEAS group    | Control group       |                |                          |
| AoLi [14]              | 2020 | 35          | TEAS          | Shame teas          | Hegu (LI4), Neiguan (PC6), Zusanli (ST36) | 5/3/1 | Breast cancer surgery    |
| JihengChen [15]        | 2020 | 40          | TEAS          | Shame teas          | Hegu (LI4), Neiguan (PC6), Houxi (SI3), Zhigou (TE6) Zusanli (ST36) | 5/3/4 | Lung cancer surgery      |
| MiaoMiaoLi [16]        | 2020 | 54          | TEAS          | Shame teas          | Hegu (LI4), Waiguan (TE5), Jinmen (BL63), Taichong (LR3), Zusanli (ST36), Qixu (GB40), Tianshu (BL10), Cuanzhu (BL2), Yuyao (EXHN4) | 2/3  | Cesarean section         |
| XingLiu [17]           | 2015 | 44          | TEAS          | Shame teas          | Shenmen (HT7), Neiguan (PC6), Zusanli (ST36), Hegu (LI4) | 2/3/4 | Infratentorial craniotomy |
| YuanyuanChang [18]     | 2020 | 42          | TEAS          | Shame teas          | Hegu (LI4), Neiguan (P6) | 3     | Thoracoscopic surgery    |
| YanMin [19]            | 2016 | 89          | TEAS          | Shame teas          | Hegu (LI4), ashi points | 5/2/3 | Laparoscopic surgery      |
| MateuszSzmit [20]      | 2021 | 24          | TEAS + PCA    | Shame teas + PCA    | Hegu (LI4) | 3     | Laparoscopic inguinal hernia surgery |
| JianhuiGan [21]        | 2018 | 60          | TEAS          | Conventional treatment Shamen teas + PCA | Shenyu (BL23), Yinlingquen (SP9) | 5     | Ureteroscopic surgery     |
| BaoguoWang [22]        | 1997 | 25          | TEAS + PCA    | Shame teases + PCA  | Hegu (LI4) | 5/2/3/4 | Lower abdominal surgery Gynecological Laparoscopic surgery |
| YushengYao [23]        | 2015 | 35          | TEAS          | Shame teases        | Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) Weizhong (BL40), Yanglingquen (GB34), Shenmen (HT7), Neiguan (P6) | 2/3/1/4 | Gynecological Laparoscopic surgery |
| YehMeiLing [24]        | 2010 | 30          | TEAS          | Shame teases        |                       | 5     | Gynecological Laparoscopic surgery |
2.4. Data Extraction and Outcomes Assessment. All data extraction was independently undertaken by 2 reviewers using predesigned forms. Clinical features (participants, interventions, and outcome measurements), details of the treatments, methodological characteristics, and the results of each outcome were extracted for each study. Discrepancies were handled by discussion. The following information was extracted from each trial: author, year, population, sample size, drug regimen (pathway and dose), and outcome. The primary efficacy outcome was VAS within 24 h after surgery. A VAS score of 0 indicated no pain, and a VAS score of 10 indicated the most severe pain. The secondary efficacy outcomes included postoperative opioid analgesic drug consumption and the occurrence of adverse reactions within postoperative 24–72 h. Adverse reactions included dizziness, nausea, and vomiting.

Table 2: Continued.

| Trial          | Year | Sample size | Interventions | Acupoint selections | Target outcomes | Type of surgery |
|----------------|------|-------------|---------------|---------------------|----------------|-----------------|
| YehMeiLing [25]| 2017 | 39          | TEAS group    | TEAS Conventional   | 3              | Hemorrhoid resection |
|                |      | 41          | Control group |                    |                |                 |
| XiangdiYu [26] | 2020 | 30          | TEAS group    | Shame teas          | 3              | Ambulatory breast surgery |
|                |      | 30          | Control group |                    |                |                 |
| Gaoz [27]      | 2014 | 33          | TEAS group    | Shame teas          | 2/1/4          | Laparoscopic surgery for gastric cancer |
|                |      | 32          | Control group |                    |                |                 |
| XinZhou [28]   | 2021 | 41          | TEAS group    | Conventional       | 2/4            | Abdominal surgery |
|                |      | 40          | Control group | treatment          |                |                 |
| Wzhan [29]     | 2019 | 30          | TEAS + TAP    | TAP                 | 3/1            |                 |
|                |      | 30          | Control group |                    |                |                 |

Note. TEAS, transcutaneous electrical acupoint stimulation; VAS, visual analogue scale; 1. postoperative dizzy; 2. postoperative nausea; 3. VAS; 4. postoperative vomiting; 5. postoperative analgesic dosage.

Table 3: Details of interventions.

| Trial          | Year | Time point | Postoperative opioid analgesics |
|----------------|------|------------|--------------------------------|
| AoLi [14]      | 2020 | 30 min before induction of anesthesia at 4 and 12 h postoperation | PCA:150 ml Sufentanil 1.5 μg/kg if needed |
| JihengChen [15]| 2020 | 30 min before induction, throughout the surgical, and 6, 24, and 48 h; sufentanil 1.5 μg/kg if needed postoperation | PCIA: sufentanil 1.5 μg/mL if needed |
| MiaoMiaoLi [16]| 2020 | 60 min postoperative and twice times on the next 24, 48, and 72 h after surgery | Not mentioned |
| XingLiu [17]   | 2015 | 30 min before induction | Not mentioned |
| YuanyuanChang [18]| 2020 | 30 min preoperative, the end of surgery and 24 and 48 h after surgery | Not mentioned |
| YanMin [19]    | 2016 | 30 min before induction | Not mentioned |
| MateuszSzmit [20]| 2021 | 30 min at intervals of 2 h within 24 hours after surgery | Not mentioned |
| JianhuiGan [21]| 2018 | 30 min at 4, 8, and 12 h postoperatively and three times on the next 2 days after surgery | Not mentioned |
| BaoguoWang [22]| 1997 | 30 min every 2 h on the next 2 days after surgery | PCA: morphine 15 ml if needed |
| YushengYao [23]| 2015 | 30 min before the induction of anesthesia | Not mentioned |
| YehMeiLing [24]| 2010 | 20 min at 2 and 4 h after surgery | PCA: morphine 1 mg if needed |
| YehMeiLing [25]| 2017 | 20 min at 4, 6 h and at 7 a.m. and 11 a.m. on the next day after surgery, 4 times in total | Not mentioned |
| XiangdiYu [26]| 2020 | 30 min before induction | Not mentioned |
| Gaoz [27]      | 2014 | 30 min before induction | Not mentioned |
| XinZhou [28]   | 2021 | 30 min at 8:00 a.m. and 4:00 p.m. on the next 3 days after surgery | Not mentioned |
| Wzhan [29]     | 2019 | 30 min preoperative and postoperative | Not mentioned |

Note. TEAS, transcutaneous electrical acupoint stimulation.
2.5. Quality Assessment and Certainty of Evidence. The Cochrane Collaboration’s tool was used to evaluate the risk of bias [16] in the methodology of the included literature. We reviewed each trial and classified the risks as high, low, or unclear, including the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective reporting, and other biases, such as sample size. Trials rated a high risk of bias in 1 or more areas will be rated high risk, while trials rated a low risk of bias in all aspects will be rated low risk. Two researchers independently performed the quality evaluation of the included articles.

2.6. Statistical Analysis. RevMan 5.4 and STATA14.0 software provided by the Cochrane Collaboration were used for data analysis. Continuous variables were analyzed using mean difference (MDs) or standardized mean difference (SMDs) and 95% CIs. Relative risk (RR) and 95%CI were used for dichotomous data. The heterogeneity between the results of the study was examined using the Q test (test level is $\alpha = 0.1$), and the magnitude of heterogeneity was judged by combining the findings with the I2 test. Heterogeneity is expressed as $p$ and $I^2$; if $p > 0.10$ and $I^2 < 50\%$, a fixed effects model was adopted; otherwise, a random effects model was chosen. Sensitivity analysis and subgroup analyses were conducted to assess the stability of results and detect the potential source of heterogeneity. Publication bias was analyzed by performing funnel plots qualitatively and estimated by Egger’s test quantitatively.

3. Results

3.1. Trial Selection. Based on our search strategy, a total of 1277 articles were extracted from the above databases. We first excluded 404 repetitive articles, and then we excluded 852 articles according to the title and abstract. Then, 21 articles were identified for full-text review. Of these, 5 articles were excluded for lack of complete data. Finally, 16 studies [17–32] were included (Figure 1).

3.2. Trial Characteristics. The characteristics of the included trials are presented in Tables 2 and 3. The trials were published between 1997 and 2021. Among the 16 RCTs included, 11 papers were published in the last 5 years (64.7%). Sample sizes ranged from 24 to 90 patients, and a total of 1305 patients were included, with 651 (49.8%) in the TEAS group and 654 (50.1%) in the control group. The population mainly involved patients with pain after surgery. All trials reported efficacy and safety outcomes. The details of the risk of bias assessment for each included trial are summarized in Figure 2. Overall, 7 trials were classified as low risk of bias, 8 as unclear risk of bias, and 1 as high risk.

3.3. Efficacy and Safety of TEAS for the Treatment of Postoperative Pain VAS. The meta-analysis combined data from 1019 participants (control group = 511 and intervention = 508). We used a standardized mean difference model to complete a meta-analysis of the pain degree at 24 h after the TEAS intervention in these twelve RCTs. Through meta-analysis, we found that TEAS can significantly reduce VAS scores of patients (SMD = −1.51, 95% CI = −2.20−−0.82, $I^2 = 96\%$) (Figure 3(a)). Then, we stratified the study according to the type of open surgery and minimally invasive surgery (Figure 3(b)). SMD shows that
| Study or Subgroup | Experimental Mean | Control Mean | Weight (%) | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Fixed, 95% CI |
|------------------|------------------|--------------|------------|----------------------------------------|--------------------------------------|
| Aoli 2020        | 2.4              | 35           | 2.9 0.6    | 35 8.3 -0.90 [-1.39, -0.40]           |                                      |
| BaoguoWang1997   | 4.4              | 23           | 4.8 2.2    | 35 8.4 -0.17 [-0.73, 0.38]            |                                      |
| Jianhuig 2018    | 2.2              | 60           | 3.4 0.8    | 60 8.6 -1.40 [-1.80, -1.00]          |                                      |
| Jiheng Chen2020  | 2.9              | 40           | 6 0.6    | 40 7.1 -6.86 [-8.04, -5.69]          |                                      |
| MateuszSzmit 2021| 1.3              | 24           | 2.9 1.5  | 24 8.3 -1.23 [-1.86, -0.61]          |                                      |
| Miaomiao LI2020  | 2                | 54           | 2.6 0.1   | 54 7.7 -5.96 [-6.85, -5.06]          |                                      |
| Wzhan 2019       | 1.7              | 30           | 2 3      | 30 8.5 -0.11 [-0.62, 0.39]           |                                      |
| Xingliu 2015     | 2.6              | 44           | 3.7 2.6   | 44 8.6 -0.88 [-0.96, -0.10]          |                                      |
| YanMin 2016      | 3.5              | 89           | 4.1 1     | 90 8.7 -0.63 [-0.93, -0.33]          |                                      |
| YuanYuChang 2020 | 2.8              | 42           | 3.2 1.1   | 43 8.6 -0.36 [-0.79, 0.07]          |                                      |
| YushengYao2015   | 1.5              | 35           | 2.5 1.2   | 36 8.5 -0.65 [-1.13, -0.17]          |                                      |
| YuXiangdi 2020   | 3.7              | 30           | 4.7 1.5   | 30 8.5 -0.66 [-1.18, -0.14]          |                                      |

Total (95% CI) 508 511 100.0 -1.51 [-2.20, -0.82]

Heterogeneity: Tau² = 1.39; Chi² = 259.03, df = 11 (P < 0.00001); I² = 96%
Test for overall effect: Z = 12.53 (P < 0.00001)

(a)

Figure 3: (a) Forest plots comparing the VAS at 24 h between the TEAS and control groups; (b) subgroup analysis of the effect of TEAS for open surgery and minimally invasive surgery.

| Study or Subgroup | Experimental Events | Control Events | Weight (%) | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|------------------|---------------------|----------------|------------|------------------------------|------------------------------|
| Aoli 2020        | 7                   | 35             | 9 35 14.2  | 0.78 [0.33, 1.86]            |                              |
| Gaoz 2014        | 7                   | 32             | 17 33 26.4 | 0.42 [0.20, 0.88]            |                              |
| Wzhan 2019       | 2                   | 30             | 10 30 15.8 | 0.20 [0.05, 0.84]            |                              |
| YushengYao2015   | 14                  | 35             | 28 36 43.6 | 0.51 [0.33, 0.80]            |                              |

Total (95% CI) 320 323 63.4 -0.91 [-1.08, -0.74]

Heterogeneity: Chi² = 117.11, df = 6 (P < 0.00001); I² = 97%
Test for overall effect: Z = 10.42 (P < 0.00001)

(b)

Figure 4: Forest plots comparing the incidence of postoperative dizziness between the TEAS and control groups.
Heterogeneity: Tau

6. Incidence of Postoperative Dizziness. The meta-analysis combined data from 266 participants (control group = 134 and intervention = 132). Four studies compared the incidence of postoperative dizziness within postoperative 24–72 h. The incidence of dizziness was significantly lower in the TEAS group than in the control group (RR = 0.48, 95% CI 0.34–0.68, I2 = 0%) (Figure 4).

3.5. Incidences of Postoperative Nausea. The meta-analysis combined data from 484 participants (control group = 241 and intervention = 243). Seven studies compared the incidence of postoperative nausea within postoperative 24–72 h. The incidence of postoperative nausea was lower in the TEAS group than in the control group, but this was not statistically significant (RR = 0.66, 95% CI 0.44–1.01, I2 = 69%) (Figure 5).

3.6. Incidence of Postoperative Vomiting. The meta-analysis combined data from 435 participants (control group = 217 and intervention = 218). Six studies compared the incidence of postoperative vomiting within postoperative 24–72 h. Among them, the article XinZhou 2021 did not have the occurrence of vomiting. Compared with the control group, the TEAS group significantly reduced the incidence of postoperative vomiting (RR = 0.49, 95% CI = 0.24–1.00, I2 = 51%) (Figure 6). We then conducted a sensitivity analysis to further explore the heterogeneity of included studies, which showed that the results of studies were relatively stable and reliable.

3.7. Postoperative Opioid Analgesic Consumption. The meta-analysis combined data from 428 participants (control group = 214 and intervention = 214). Six studies compared postoperative opioid analgesic consumption. Compared with the control group, the TEAS group significantly reduced postoperative analgesic consumption (SMD = −2.10, 95% CI = −3.37–−0.82, I2 = 96%) (Figure 7). The sensitivity analysis findings indicated that the results were robust and reliable.

3.8. Publication Bias Analysis and Sensitivity Analysis. There are more than 10 studies on the VAS score after surgery. Sensitivity analyses were performed by removing one study each time to assess the influence of an individual study on the overall outcomes. No significant changes were observed after combining the results, indicating that the results of the study were relatively stable. Then, Egger’s test...
Test for overall effect: Z = 3.22 (P = 0.001) −4 −2 0 2 4

4. Discussion

TEAS has been widely accepted and used worldwide. To our knowledge, our meta-analysis is the first to research the efficacy and safety of TEAS in treating postoperative pain. Our research shows that TEAS can significantly decrease VAS scores of patients. According to subgroup analysis, we found that VAS scores decreased significantly after minimally invasive surgery and open surgery. Minimally invasive surgery is the direction of surgery [30]. TEAS selections need to be considered to improve the efficacy and clinical quality of patients. In addition, our study revealed that TEAS provides broadly generalizable benefits during the postoperative recovery period and helps to accelerate the progress of enhanced recovery after surgery.

According to the theory of traditional Chinese medicine, acupuncture meridians represent “channels” through which energy called “meridian qi” flows [31]. Acupuncture has been utilized in Chinese health care for at least 2500 years, which is a technique for balancing the flow of energy [32]. The underlying mechanisms of TEAS’s analgesic effects have not been clearly clarified. Basic studies have shown that TEAS can achieve the intervention effect on pain sensation and can be exerted via multiple mechanisms. (1) TEAS may produce analgesia by promoting the release of endogenous opioid peptides [33]. (2) TEAS inhibit the production of endogenous pain-causing substances [33]. (3) TEAS to intervene in the MAPK signal transduction pathway to play analgesic effect [34]. (4) TEAS inhibit pain sensitization. The early peripheral sensitization of neuropathic pain may be interfered by downregulating TRPV1 phosphorylation level and calcitonin gene-related peptide expression level of injured DRG [35].

Postoperative pain contributes to increased morbidity, impaired physical function and quality of life, slowed recovery, and increased cost of care [36]. Given the unclear formation mechanism of postoperative pain, it remains one of the most challenging problems in clinical pain therapeutics. Studies have shown that TEAS could regulate the function of the hypothalamic pituitary-adrenal (HPA) axis and antagonize the hyperfunction of the HPA axis [37]. The HPA axis has many functions including regulation of appetite, sleep, sexual desires, and adaptation to stress [38]. Dysfunction of the HPA axis is thought to be primarily responsible for psychological/behavioral symptoms (pain sensitivity, depression, and fatigue) [38]. An RCT showed that TAES treatment can increase the serum levels of IL-2 and IFN-γ, and decreased IL-4 secretion and return the aforementioned cellular immune factors to the preoperative control value at a faster rate [39]. These results suggest that TEAS can reduce postoperative immune dysfunction by changing the expression of Th1/Th2 cell-associated cytokines [39]. Simultaneously, some preclinical studies have also shown that TEAS can attenuate cognitive deficits by inhibiting neuronal peroxide reactions in hippocampus tissue and inflammation of the central and peripheral nervous systems [40]. The major pathway is the cholinergic anti-inflammatory pathway (CAP). TEAS can stimulate the vagus nerve to activate CAP so as to inhibit the production of proinflammatory cytokines [41]. Studies have revealed that low-frequency electrical stimulation can release enkephalins and endorphins from the central nervous system [42]. High frequency electrical stimulation induces the release of endorphins from the spinal cord. Low frequency/high frequency alternating density waves can simultaneously stimulate these three peptides to produce a synergistic analgesic effect [43]. TEAS may affect 5-HT transmission by...
activating 5-HT and norepinephrine fibers to promote gastrointestinal motility and reduce the incidence of nausea and vomiting [44]. Meanwhile, there is a dose-response relationship between opioid dosage and associated side effects [45]. Opioid analgesics are commonly used postoperative analgesics in clinics, but they easily cause dose-dependent respiratory depression, gastrointestinal reaction, urinary retention, skin itching, and other adverse reactions [46]. Our study revealed that the application of TEAS was associated with lower opioid analgesic consumption. Therefore, TEAS provides a nondrug alternative for multimodal analgesia for postoperative pain.

5. Conclusions

TEAS is a reasonable modality to incorporate into a multimodal management approach for postoperative pain. TEAS can reduce postoperative pain as well as the incidence of dizziness, nausea, and vomiting and the number of analgesics used after surgery. Owing to the limitations, further large-scale and well-designed studies are required to verify and expand on our conclusion.

Data Availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure

Dan Wang and Hongshuo Shi are the co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] M. Tanaka, N. Török, F. Tóth, Á. Szabó, and L. Vécsei, “Co-players in chronic pain: neuroinflammation and the tryptophan-kynurenine metabolic pathway,” Biomedicines, vol. 9, no. 8, 2021.
[2] S. N. Raja, D. B. Carr, M. Cohen et al., “The revised international association for the study of pain definition of pain: concepts, challenges, and compromises,” Pain, vol. 161, no. 9, pp. 1976–1982, 2020.
[3] N. Rawal, “Current issues in postoperative pain management,” European Journal of Anaesthesiology, vol. 33, no. 3, pp. 160–171, 2016.
[4] H. Kehlet, T. S. Jensen, and C. J. Woolf, “Persistent post-surgical pain: risk factors and prevention,” The Lancet, vol. 367, no. 9522, pp. 1618–1625, 2006.
[5] E. C. Wick, M. C. Grant, and C. L. Wu, “Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques,” JAMA Surgery, vol. 152, no. 7, pp. 691–697, 2017.
[6] H. C. Hemmings Jr. and D. G. Lambert, “The good, the bad, and the ugly: the many faces of opioids,” British Journal of Anaesthesia, vol. 122, no. 6, pp. 705–707, 2019.
[7] A.-M. Schierning, P. McGettigan, and G. Gislason, “Cardiovascular effects and safety of (non-aspirin) NSAIDs,” Nature Reviews Cardiology, vol. 17, no. 9, pp. 574–584, 2020.
[8] D. E. Becker and K. L. Reed, “Local anesthetics: review of pharmacological considerations,” Anesthesia Progress, vol. 59, no. 2, pp. 90–102, 2012.
[9] S. Shariifiari, J. J. Shuster, and M. D. Bishop, “Adding electrical stimulation during standard rehabilitation after stroke to improve motor function. a systematic review and meta-analysis,” Annals of Physical and Rehabilitation Medicine, vol. 61, no. 5, pp. 339–344, 2018.
[10] A. J. Vickers, E. A. Vertosick, G. Lewith et al., “Acupuncture for chronic pain: update of an individual patient data meta-analysis,” The Journal of Pain, vol. 19, no. 5, pp. 455–474, 2018.
[11] H. Shimbara, M. Okubo, K. Kimura, K. Mizunuma, and E. Sumiya, “Contributions of nitric oxide and prostaglandins to the local increase in muscle blood flow following manual acupuncture in rats,” Acupuncture in Medicine, vol. 33, no. 1, pp. 65–71, 2015.
[12] Y. Gong, N. Li, Z. Lv et al., “The neuro-immune microenvironment of acupoints-initiation of acupuncture effectiveness,” Journal of Leukocyte Biology, vol. 108, no. 1, pp. 189–198, 2020.
[13] M. Cai, J.-H. Lee, and E. J. Yang, “Electroacupuncture attenuates cognition impairment via anti-neuroinflammation in an Alzheimer’s disease animal model,” Journal of Neuroinflammation, vol. 16, no. 1, p. 264, 2019.
[14] L. Ao, J. Shi, Y. Bai, S. Zhang, and J. Gan, “Effects of transcutaneous electrical acupoint stimulation on perioperative immune function and postoperative analgesia in patients undergoing radical mastectomy: a randomized controlled trial,” Experimental and Therapeutic Medicine, vol. 21, no. 3, p. 184, 2021.
[15] J. Chen, Y. Zhang, X. Li et al., “Efficacy of transcutaneous electrical acupoint stimulation combined with general anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: a randomized, double-blind, placebo-controlled trial,” Thoracic Cancer, vol. 11, no. 4, pp. 928–934, 2020.
[16] M. Li, F. Xu, M. Liu et al., “Effects and mechanisms of transcutaneous electrical acustimulation on postoperative recovery after elective cesarean section,” Neuromodulation: Journal of the International Neuromodulation Society, vol. 23, no. 6, pp. 838–846, 2020.
[17] X. Liu, S. Li, B. Wang, L. An, X. Ren, and H. Wu, “Intraoperative and postoperative anaesthetic and analgesic effect of multipoint transcutaneous electrical acupuncture stimulation combined with sufentanil anaesthesia in patients undergoing supratentorial craniotomy,” Acupuncture in Medicine, vol. 33, no. 4, pp. 270–276, 2015.
[18] B. Song, Y. Chang, Y. Li, and J. Zhu, “Effects of transcutaneous electrical acupoint stimulation on the postoperative sleep quality and pain of patients after video-assisted thoracoscopic surgery: a prospective, randomized controlled trial,” Nature and Science of Sleep, vol. 12, pp. 809–819, 2020.
[19] K. Sun, T. Xing, F. Zhang et al., “Perioperative transcutaneous electrical acupoint stimulation for postoperative pain relief following laparoscopic surgery,” The Clinical Journal of Pain, vol. 33, no. 4, pp. 340–347, 2017.
[20] M. Szmit, S. Agrawal, W. Go´zdzik et al., “Transcutaneous electrical acupoint stimulation reduces postoperative analgesic requirement in patients undergoing inguinal hernia repair: a randomized, placebo-controlled study,” Journal of Clinical Medicine, vol. 10, no. 1, 2021.
[21] Q. Tu, J. Gan, J. Shi, H. Yu, S. He, and J. Zhang, “Effect of transcutaneous electrical acupoint stimulation on...
postoperative analgesia after ureteroscopic lithotripsy: a randomized controlled trial,” *Urolithiasis*, vol. 47, pp. 1–9, 2018.

[22] B. Wang, J. Tang, P. F. White et al., “Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement,” *Anesthesia & Analgesia*, vol. 85, no. 2, pp. 406–413, 1997.

[23] Y. Yao, Q. Zhao, C. Gong et al., “Transcutaneous electrical acupoint stimulation improves the postoperative quality of recovery and analgesia after gynecological laparoscopic surgery: a randomized controlled trial,” *Evid Based Complementary Alternative Medicine*, vol. 2015, Article ID 324360, 6 pages, 2015.

[24] M. L. Yeh, Y. C. Chung, K. M. Chen, and H. H. Chen, “Pain reduction of acupoint electrical stimulation for patients with spinal surgery: a placebo-controlled study,” *International Journal of Nursing Studies*, vol. 48, no. 6, pp. 703–9, 2011.

[25] M.-L. Yeh, Y.-C. Chung, L.-C. Hsu, and S.-H. Hung, “Effect of transcutaneous acupoint electrical stimulation on post-hemorrhoidectomy-associated pain, anxiety, and heart rate variability: a randomized-controlled study,” *Clinical Nursing Research*, vol. 27, no. 4, pp. 450–466, 2018.

[26] X. Yu, F. Zhang, and B. Chen, “The effect of TEAS on the quality of early recovery in patients undergoing gynecological laparoscopic surgery: a prospective, randomized, placebo-controlled trial,” *Trials*, vol. 21, no. 1, p. 43, 2020.

[27] Q. Zhang, Z. Gao, H. Wang et al., “The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial,” *Anaesthesia*, vol. 69, no. 8, pp. 832–839, 2014.

[28] X. Zhou, S.-G. Cao, X.-J. Tan et al., “Effects of transcutaneous electrical acupoint stimulation (TEAS) on postoperative recovery in patients with gastric cancer: a randomized controlled trial,” *Cancer Management and Research*, vol. 13, pp. 1449–1458, 2021.

[29] W. Zhan and W. Tian, “Addition of transcutaneous electric acupoint stimulation to transverse abdominis plane block for postoperative analgesia in abdominal surgery: a randomized controlled trial,” *European Journal of Integrative Medicine*, vol. 35, 2020.

[30] P.-Y. Chang and M. Y. Wang, “Minimally invasive spinal deformity surgery,” *Neurosurgery*, vol. 63, no. Suppl 1, pp. 43–51, 2016.

[31] R. C. de Souza, M. Pansini, G. Arruda, C. Valente, and M. L. Brioscchi, “Laser acupuncture causes thermal changes in small intestine meridian pathway,” *Lasers in Medical Science*, vol. 31, no. 8, pp. 1645–1649, 2016.

[32] Y. Zhang, J.-J. Xing, J. Li, B.-Y. Zeng, and F.-R. Liang, “History of acupuncture research,” *International Review of Neurobiology*, vol. 111, pp. 1–23, 2013.

[33] Z.-Q. Zhao, “Neural mechanism underlying acupuncture analgesia,” *Progress in Neurobiology*, vol. 85, no. 4, pp. 355–375, 2008.

[34] L. Wang, J. An, S. Song et al., “Electroacupuncture preserves intestinal barrier integrity through modulating the gut microbiota in DSS-induced chronic colitis,” *Life Sciences*, vol. 261, Article ID 118473, 2020.

[35] Y.-W. Lin, A. I. W. Chou, H. Su, and K.-P. Su, “Transient receptor potential V1 (TRPV1) modulates the therapeutic effects for comorbidity of pain and depression: the common molecular implication for electroacupuncture and omega-3 polyunsaturated fatty acids,” *Brain, Behavior, and Immunity*, vol. 89, pp. 604–614, 2020.